Testimonials From Our Speakers

"The long-awaited breakthroughs in targeting mutant RAS are now with us, and research and development in the RAS field is advancing rapidly. This meeting will bring together top researchers in the field. Attendance and participation will be critical to stay with the field."

Steve Kelsey

Steve Kelsey
President, Research & Development
Revolution Medicines

Grahame Mckenzie

Grahame Mckenzie
Chief Scientific Officer
PhoreMost

"This event will bring together key opinion leaders from both academia and drug discovery in order to deliver a truly translational meeting focused on how best to tackle oncogenic RAS."

"The field of RAS inhibitory drugs has exploded in the last few years and this meeting will be an excellent opportunity to catch up on the latest developments in this fast-moving area."

Julian Downward

Julian Downward
Associate Research Director
Francis Crick Institute

Stig Hansen

Stig Hansen
Chief Executive Officer
Carmot Therapeutics

"This meeting provides a great opportunity to discuss new approaches to this rapidly advancing area in cancer therapeutics."

"Targeting oncogenic KRAS signalling is one of the most exciting challenges in cancer biology. Recent clinical trials with KRAS G12C specific inhibitors open up a first glimpse on the potential of targeting oncogenic KRAS in general. Networking, exchange of ideas and experiences in the KRAS field is one of the major values of this meeting."

Michael Gmachl

Michael Gmachl
Principal Scientist, Regional Center Austria
Boehringer Ingelheim